Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activation of calcium-activated, phospholipid-dependent
protein kinase C
by diacylglycerol and phorbol esters has been shown to mediate release of hormones in many systems. To determine whether
protein kinase C
activation is also involved in the regulation of prolactin release from human decidua, we have examined the effects of various acylglycerols and phorbol esters on the synthesis and release of prolactin from cultured human decidual cells. sn-1,2-Dioctanoylglycerol (diC8), which is known to stimulate
protein kinase C
in other systems, inhibited prolactin release in a dose-dependent manner with maximal inhibition of 53.1% (P less than 0.01) at 100 microM. Diolein (100 microM), which also stimulates
protein kinase C
activity in some systems, inhibited prolactin release by 21.3% (P less than 0.05).
Distearin
and dipalmitin, which are much less effective in activating
protein kinase C
, and monopalmitin and tripalmitin, which do not activate
protein kinase C
, had no significant effect on prolactin release. Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate
protein kinase C
in other systems, also inhibited the release of prolactin, while the
protein kinase C
inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. The inhibition of prolactin release was secondary to a decrease in prolactin synthesis. The amounts of prolactin synthesized by cells exposed to diC8 (300 microM) or PMA (10(-7) M) for 30 min were 56.3 and 50.0% less than that synthesized by control cells (P less than 0.01 in each instance).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Activation of protein kinase C inhibits synthesis and release of decidual prolactin. 374 Feb 56